Table 1.
First generation | |
---|---|
Imatinib | First-line and second/subsequent-linea, all disease phases |
Second generation | |
Dasatinib | First-line and second/subsequent-line, all disease phases |
Nilotinib | First-line and second/subsequent-line, CP and AP only |
Bosutinib | Third-line or when imatinib, dasatinib or nilotinib are not considered appropriate, all disease phases |
Third generation | |
Ponatinib | Second/subsequent-line if T315I+ or when no other TKI is considered appropriate, all disease phases |
abeing the weaker of all, imatinib is rarely considered as second/subsequent line option especially in case of resistance